Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $19.00

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have received an average recommendation of "Hold" from the six ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $19.00.

A number of equities analysts have weighed in on the stock. JMP Securities cut their price target on shares of Enanta Pharmaceuticals from $23.00 to $22.00 and set a "market outperform" rating on the stock in a research note on Tuesday, May 7th. StockNews.com raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, May 8th. Finally, HC Wainwright cut their target price on shares of Enanta Pharmaceuticals from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Tuesday, May 7th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Armistice Capital LLC grew its holdings in Enanta Pharmaceuticals by 3.1% during the 3rd quarter. Armistice Capital LLC now owns 2,100,000 shares of the biotechnology company's stock worth $23,457,000 after acquiring an additional 64,000 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 3.5% in the 1st quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company's stock valued at $36,579,000 after buying an additional 70,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 7.5% in the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company's stock valued at $33,664,000 after buying an additional 134,292 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 1.3% in the 1st quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company's stock valued at $14,906,000 after buying an additional 10,952 shares during the period. Finally, Krensavage Asset Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 6.9% in the 3rd quarter. Krensavage Asset Management LLC now owns 735,103 shares of the biotechnology company's stock valued at $8,211,000 after buying an additional 47,490 shares during the period. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Price Performance

NASDAQ:ENTA traded up $0.37 during trading hours on Friday, reaching $12.91. 679,229 shares of the company were exchanged, compared to its average volume of 125,777. The firm has a market cap of $273.43 million, a price-to-earnings ratio of -2.07 and a beta of 0.56. Enanta Pharmaceuticals has a 52-week low of $8.08 and a 52-week high of $26.91. The stock has a 50 day simple moving average of $13.74 and a 200 day simple moving average of $12.64.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($1.47) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.21). The company had revenue of $17.05 million for the quarter, compared to analysts' expectations of $16.47 million. Enanta Pharmaceuticals had a negative return on equity of 64.85% and a negative net margin of 180.76%. On average, analysts predict that Enanta Pharmaceuticals will post -5.95 EPS for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.